
Anna McGlothlin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6740239/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hypothermia for Patients Requiring Evacuation of Subdural Hematoma: A Multicenter Randomized Clinical Trial. Neurocritical Care, 2022, 36, 560-572.	2.4	7
2	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 227.	7.4	89
3	Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically III Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1247.	7.4	83
4	Optimizing Sample Size Allocation and Power in a Bayesian Two-Stage Drop-the-Losers Design. American Statistician, 2021, 75, 66-75.	1.6	1
5	Sutureless versus conventional bioprostheses for aortic valve replacement in severe symptomatic aortic valve stenosis. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 920-932.	0.8	55
6	Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis. JAMA - Journal of the American Medical Association, 2021, 325, 742.	7.4	168
7	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 384, 1491-1502.	27.0	1,419
8	Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials. Therapeutic Innovation and Regulatory Science, 2021, 55, 1145-1154.	1.6	31
9	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Medicine, 2021, 47, 867-886.	8.2	65
10	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	27.0	778
11	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 777-789.	27.0	712
12	Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1690.	7.4	169
13	The design of a Bayesian adaptive clinical trial of tranexamic acid in severely injured children. Trials, 2021, 22, 769.	1.6	6
14	Comparison of methods for control allocation in multiple arm studies using response adaptive randomization. Clinical Trials, 2020, 17, 52-60.	1.6	33
15	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1317.	7.4	671
16	Comparison of response adaptive randomization features in multiarm clinical trials with control. Pharmaceutical Statistics, 2020, 19, 602-612.	1.3	16
17	In response: Letter on update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol. Trials, 2020, 21, 351.	1.6	1

18 The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5

ANNA MCGLOTHLIN

#	Article	IF	CITATIONS
19	The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) Protocol: a prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. Trials, 2019, 20, 197.	1.6	57
20	Update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol: statistical analysis plan for a prospective, multicenter, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. Trials, 2019, 20, 670.	1.6	7
21	Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 315-326.	2.3	25
22	Interpretation of Clinical Trials That Stopped Early. JAMA - Journal of the American Medical Association, 2016, 315, 1646.	7.4	29
23	Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes. JAMA Oncology, 2016, 2, 751.	7.1	243
24	Binary Regression with Misclassified Response and Covariate Subject to Measurement Error: a Bayesian Approach. Biometrical Journal, 2008, 50, 123-134.	1.0	18
25	PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. Leukemia and Lymphoma, 0, , 1-16.	1.3	1